Track topics on Twitter Track topics that are important to you
Neon Therapeutics (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. As quoted in the press release: In addition, Neon Therapeutics has granted the underwriters a 30-day option to … Continued
The post Neon Therapeutics Announces Pricing of Initial Public Offerings appeared first on Investing News Network.
Original Article: Neon Therapeutics Announces Pricing of Initial Public OfferingsNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...